PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. Eltrombopag demonstrated dose-proportional increase in exposure between doses of 50 to 150 mg/day in healthy adult subjects. Eltrombopag AUC was approximately 1.7-fold higher in patients with persistent or chronic ITP and approximately 2.8-fold higher in patients with HCV compared to healthy subjects. Steady-state was achieved after approximately week of once daily treatment, with geometric mean accumulation ratio of 1.56 (90% confidence interval 1.20, 1.63) at 75 mg/day. Eltrombopag for oral suspension delivered 22% higher plasma AUC 0-INFthan the tablet formulation. Absorption Eltrombopag is absorbed with peak concentration occurring to hours after oral administration. Oral absorption of drug-related material following administration of single 75 mg solution dose was estimated to be at least 52%. Effect of Food standard high-fat breakfast (876 calories, 52 fat, 71 carbohydrate, 34 protein, and 427 mg calcium) significantly decreased plasma eltrombopag AUC 0-INFby approximately 59% and maxby 65% and delayed maxby hour. The decrease in exposure is primarily due to the high calcium content. meal low in calcium (<= 50 mg calcium) did not significantly impact plasma eltrombopag exposure, regardless of calorie and fat content. The effect of administration of single 25 mg dose of eltrombopag for oral suspension with high-calcium, moderate-fat, moderate calorie meal on AUC 0-INFand maxin healthy adult subjects is presented in Table 14. Table 14. Effect on Plasma Eltrombopag Pharmacokinetic Parameters After Administration of Single 25 mg Dose of Eltrombopag for Oral Suspension With High Calcium Meal ain Healthy Adult Subjects Timing of eltrombopag for oral suspension doseMean (90% CI) reduction in plasma eltrombopag AUC 0-INF Mean (90% CI) reduction in plasma eltrombopag max With high-calcium, moderate-fat, moderate-calorie meal 75% (71%, 88%) 79% (76%, 82%) hours after the high-calcium, moderate-fat, moderate-calorie meal 47% (40%, 53%) 48% (40%, 54%) hours before the high-calcium, moderate-fat, moderate-calorie meal 20% (9%, 29%) 14% (2%, 25%) a372 calories, g fat, and 448 mg calcium. Distribution The concentration of eltrombopag in blood cells is approximately 50% to 79% of plasma concentrations based on radiolabel study. In vitrostudies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%). Eltrombopag is substrate of BCRP, but is not substrate for P-glycoprotein (P-gp) or OATP1B1. Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP. Metabolism:Absorbed eltrombopag is extensively metabolized, predominantly through pathways, including cleavage, oxidation, and conjugation with glucuronic acid, glutathione, or cysteine. In vitrostudies suggest that CYP1A2 and CYP2C8 are responsible for the oxidative metabolism of eltrombopag. UGT1A1 and UGT1A3 are responsible for the glucuronidation of eltrombopag. Excretion: The predominant route of eltrombopag excretion is via feces (59%), and 31% of the dose is found in the urine. Unchanged eltrombopag in feces accounts for approximately 20% of the dose; unchanged eltrombopag is not detectable in urine. Specific Populations Ethnicity Eltrombopag concentrations in East-/Southeast-Asian ancestry patients with ITP or chronic hepatitis C, were 50% to 55% higher compared with non-Asian subjects [see Dosage and Administration (2.1, 2.3)]. Eltrombopag exposure in healthy African-American subjects was approximately 40% higher than that observed in Caucasian subjects in one clinical pharmacology trial and similar in three other clinical pharmacology trials. The effect of African-American ethnicity on exposure and related safety and efficacy of eltrombopag has not been established. Hepatic Impairment Following single dose of eltrombopag (50 mg), plasma eltrombopag AUC 0-INFwas 41% higher in patients with mild hepatic impairment (Child-Pugh class A) compared with subjects with normal hepatic function. Plasma eltrombopag AUC 0-INFwas approximately 2-fold higher in patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) compared with subjects with normal hepatic function. The half-life of eltrombopag was prolonged 2-fold in these patients. This clinical trial did not evaluate protein-binding effects. Chronic Liver Disease Following repeat doses of eltrombopag in patients with thrombocytopenia and with chronic liver disease, mild hepatic impairment resulted in an 87% to 110% higher plasma eltrombopag AUC (0-)and moderate hepatic impairment resulted in approximately 141% to 240% higher plasma eltrombopag AUC (0-)values compared with patients with normal hepatic function. The half-life of eltrombopag was prolonged 3-fold in patients with mild hepatic impairment and 4-fold in patients with moderate hepatic impairment. This clinical trial did not evaluate protein-binding effects. Chronic Hepatitis Patients with chronic hepatitis treated with eltrombopag had higher plasma AUC( 0-) values as compared with healthy subjects, and AUC( 0-) increased with increasing Child-Pugh score. Patients with chronic hepatitis and mild hepatic impairment had approximately 100% to 144% higher plasma AUC( 0-) compared with healthy subjects. This clinical trial did not evaluate protein-binding effects. Renal Impairment Following single dose of eltrombopag (50 mg), the average total plasma eltrombopag AUC 0-INFwas 32% to 36% lower in subjects with mild (estimated creatinine clearance (CLCr) by Cockcroft-Gault equation: 50 to 80 mL/min), to moderate (CLCr of 30 to 49 mL/min) renal impairment and 60% lower in subjects with severe (CLCr less than 30 mL/min) renal impairment compared with healthy subjects. The effect of renal impairment on unbound (active) eltrombopag exposure has not been assessed. Pediatric Patients The pharmacokinetics of eltrombopag have been evaluated in 168 pediatric patients year and older with ITP dosed once daily in two trials. Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight. East-/Southeast-Asian pediatric patients with ITP had approximately 43% higher plasma eltrombopag AUC (0-)values as compared with non-Asian patients. Plasma eltrombopag AUC (0-)and maxin pediatric patients aged 12 to 17 years was similar to that observed in adults. The pharmacokinetic parameters of eltrombopag in pediatric patients with ITP are shown in Table 15. Table 15. Geometric Mean (95% CI) Steady-state Plasma Eltrombopag Pharmacokinetic Parameters ain Patients With ITP (Normalized to Once-daily 50 mg Dose) AgeC max b(mcg/mL)AUC (0- )b(mcg.hr/mL) Adults (n 108) 7.03 (6.44, 7.68) 101 (91.4, 113) 12 to 17 years (n 62) 6.80 (6.17, 7.50) 103 (91.1, 116) to 11 years (n 68) 10.3 (9.42, 11.2) 153 (137, 170) to years (n 38) 11.6 (10.4, 12.9) 162 (139, 187) aPK parameters presented as geometric mean (95% CI). bBased on population PK post-hoc estimates. Drug Interaction Studies Clinical Studies Effect of Drugs on Eltrombopag Effect of Polyvalent Cation-containing Antacids on Eltrombopag: The coadministration of single dose of eltrombopag (75 mg) with polyvalent cation-containing antacid (1,524 mg aluminum hydroxide, 1,425 mg magnesium carbonate, and sodium alginate) decreased plasma eltrombopag AUC 0-INFand maxby approximately 70%. The contribution of sodium alginate to this interaction is not known. Effect of HIV Protease Inhibitors on Eltrombopag: The coadministration of repeat-dose lopinavir 400 mg/ritonavir 100 mg (twice daily) with single dose of eltrombopag (100 mg) decreased plasma eltrombopag AUC 0-INFby 17%. Effect of HCV Protease Inhibitors on Eltrombopag: The coadministration of repeat-dose telaprevir (750 mg every hours) or boceprevir (800 mg every hours) with single dose of eltrombopag (200 mg) to healthy adult subjects in clinical trial did not alter plasma eltrombopag AUC 0-INFor maxto significant extent. Effect of Cyclosporine on Eltrombopag: The coadministration of single dose of eltrombopag (50 mg) with single dose of an OATP and BCRP inhibitor cyclosporine (200 mg or 600 mg) decreased plasma eltrombopag AUC 0-INFby 18% to 24% and maxby 25% to 39%. Effect of Pegylated Interferon alfa-2a Ribavirin and Pegylated Interferon alfa-2b Ribavirin on Eltrombopag: The presence of pegylated interferon alfa ribavirin therapy did not significantly affect the clearance of eltrombopag. Effect of Eltrombopag on Other Drugs Effect of Eltrombopag on Cytochrome P450 Enzymes Substrates: The coadministration of multiple doses of eltrombopag (75 mg once daily for days) did not result in the inhibition or induction of the metabolism of combination of probe substrates for CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP2C9 (flurbiprofen), or CYP3A4 (midazolam) in humans. Effect of Eltrombopag on Rosuvastatin: The coadministration of multiple doses of eltrombopag (75 mg once daily for days) with single dose of rosuvastatin (OATP1B1 and BCRP substrate; 10 mg) increased plasma rosuvastatin AUC 0-INFby 55% and maxby 103%. Effect of Eltrombopag on HCV Protease Inhibitors: The coadministration of repeat-dose telaprevir (750 mg every hours) or boceprevir (800 mg every hours) with single dose of eltrombopag (200 mg) to healthy adult subjects in clinical trial did not alter plasma telaprevir or boceprevir AUC 0-INFor maxto significant extent. In vitro Studies Eltrombopag Effect on Metabolic Enzymes Eltrombopag has demonstrated the potential to inhibit CYP2C8, CYP2C9, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15. Eltrombopag Effect on Transporters Eltrombopag has demonstrated the potential to inhibit OATP1B1 and BCRP. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following clinically significant adverse reactions associated with eltrombopag are described in other sections. Hepatic Decompensation in Patients with Chronic Hepatitis [see Warnings and Precautions 5.1)] Hepatotoxicity [see Warnings and Precautions 5.2)] Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia [see Warnings and Precautions 5.3)] Thrombotic/Thromboembolic Complications [see Warnings and Precautions 5.4)] Cataracts [see Warnings and Precautions 5.5)] Hepatic Decompensation in Patients with Chronic Hepatitis [see Warnings and Precautions 5.1)] Hepatotoxicity [see Warnings and Precautions 5.2)] Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia [see Warnings and Precautions 5.3)] Thrombotic/Thromboembolic Complications [see Warnings and Precautions 5.4)] Cataracts [see Warnings and Precautions 5.5)] Across all indications, the most common adverse reactions (>= 20% in any indication) were: anemia, nausea, pyrexia, alanine aminotransferase increased, cough, fatigue, headache, and diarrhea. 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Annora Pharma Private Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Persistent or Chronic Immune Thrombocytopenia Adults:In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of eltrombopag. Other serious adverse reactions included thrombotic/thromboembolic complications [see Warnings and Precautions (5.4)]. The data described below reflect exposure of eltrombopag to patients with persistent or chronic ITP aged 18 to 85 years, of whom 66% were female, in three placebo-controlled trials and one open-label extension trial [see Clinical Studies (14.1)]. Eltrombopag was administered to 330 patients for at least months and 218 patients for at least year. Table presents the most common adverse drug reactions (experienced by greater than or equal to 3% of patients receiving eltrombopag) from the three placebo-controlled trials, with higher incidence in eltrombopag versus placebo. Table 8. Adverse Reactions (>= 3%) From Three Placebo-controlled Trials in Adults With Persistent or Chronic Immune Thrombocytopenia Adverse reactionEltrombopag 50 mgn 241(%)Placebon 128(%)Nausea 3 Diarrhea 7 Upper respiratory tract infection 6 Vomiting < Urinary tract infection 5 Increased ALT 3 Myalgia 2 Oropharyngeal pain 3 Increased AST 2 Pharyngitis 2 Back pain 2 Influenza 2 Paresthesia 2 Rash 2 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. aIncludes PTs of urinary tract infection, cystitis, urinary tract infection bacterial, and bacteriuria. In the three controlled clinical persistent or chronic ITP trials, alopecia, musculoskeletal pain, blood alkaline phosphatase increased, and dry mouth were the adverse reactions reported in 2% of patients treated with eltrombopag and in no patients who received placebo. Among 302 patients with persistent or chronic ITP who received eltrombopag in the single-arm extension trial, the adverse reactions occurred in pattern similar to that seen in the placebo-controlled trials. Table presents the most common treatment-related adverse reactions (experienced by greater than or equal to 3% of patients receiving eltrombopag) from the extension trial. Table 9. Treatment-related Adverse Reactions (>= 3%) From Extension Trial in Adults With Persistent or Chronic Immune Thrombocytopenia Adverse reactionEltrombopag 50 mgn 302(%)Headache 10 ALT increased AST increased Cataract Fatigue Blood bilirubin increased Nausea Hyperbilirubinemia Diarrhea Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. In the three controlled persistent or chronic ITP trials, serum liver test abnormalities (predominantly Grade or less in severity) were reported in 11% and 7% of patients for eltrombopag and placebo, respectively. Four patients (1%) treated with eltrombopag and three patients in the placebo group (2%) discontinued treatment due to hepatobiliary laboratory abnormalities. Seventeen of the patients treated with eltrombopag in the controlled trials with hepatobiliary laboratory abnormalities were re-exposed to eltrombopag in the extension trial. Eight of these patients again experienced liver test abnormalities (less than or equal to Grade 3) resulting in discontinuation of eltrombopag in one patient. In the extension persistent or chronic ITP trial, six additional patients had eltrombopag discontinued due to liver test abnormalities (less than or equal to Grade 3). In the three controlled persistent or chronic ITP trials, cataracts developed or worsened in 7% of patients treated with eltrombopag and 7% of patients in the placebo group. All patients had documented, preexisting risk factors for cataractogenesis, including corticosteroid use. In the extension trial, cataracts developed or worsened in 11% of patients who underwent ocular examination prior to therapy with eltrombopag. Seventy-two percent of patients had preexisting risk factors, including corticosteroid use. The safety of eltrombopag was also assessed in all patients treated in adult persistent or chronic ITP clinical trials (N 763 eltrombopag -treated patients and 179 placebo-treated patients). Thromboembolic events were reported in 6% of eltrombopag-treated patients versus 0% of placebo-treated patients and thrombotic microangiopathy with acute renal failure was reported in 1% of eltrombopag-treated patients versus 0% of placebo-treated patients. In placebo-controlled trial of eltrombopag in patients with chronic liver disease and thrombocytopenia not related to ITP, six patients treated with eltrombopag and one patient in the placebo group developed portal vein thromboses [see Warnings and Precautions 5.4)]. Pediatric Patients:The data described below reflect median exposure to eltrombopag of 91 days for 107 pediatric patients (aged to 17 years) with persistent or chronic ITP, of whom 53% were female, across the randomized phase of two placebo-controlled trials. Table 10 presents the most common adverse drug reactions (experienced by greater than or equal to 3% of pediatric patients year and older receiving eltrombopag) across the two placebo-controlled trials, with higher incidence for eltrombopag versus placebo. Table 10. Adverse Reactions (>= 3%) With Higher Incidence for Eltrombopag Versus Placebo From Two Placebo-controlled Trials in Pediatric Patients Year and Older With Persistent or Chronic Immune Thrombocytopenia Adverse reactionEltrombopagn 107(%)Placebon 50(%) Upper respiratory tract infection 17 Nasopharyngitis 12 Cough 0 Diarrhea 2 Pyrexia 8 Abdominal pain 4 Oropharyngeal pain 2 Toothache 0 ALT increased 6 Rash 2 AST increased 0 Rhinorrhea 0 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. aIncludes adverse reactions or laboratory abnormalities 3 ULN. In the two controlled clinical persistent or chronic ITP trials, cataracts developed or worsened in (1%) patients treated with eltrombopag. Both patients had received chronic oral corticosteroids, risk factor for cataractogenesis. Chronic Hepatitis C-associated Thrombocytopenia:In the two placebo-controlled trials, 955 patients with chronic hepatitis C-associated thrombocytopenia received eltrombopag. Table 11 presents the most common adverse drug reactions (experienced by greater than or equal to 10% of patients receiving eltrombopag compared with placebo). Table 11. Adverse Reactions (>= 10% and Greater Than Placebo) From Two Placebo-controlled Trials in Adults With Chronic Hepatitis Adverse reaction Eltrombopag Peginterferon/Ribavirin = 955 (%) Placebo Peginterferon/Ribavirin = 484 (%) Anemia 40 35 Pyrexia 30 24 Fatigue 28 23 Headache 21 20 Nausea 19 14 Diarrhea 19 11 Decreased appetite 18 14 Influenza-like illness 18 16 Insomnia 16 15 Asthenia 16 13 Cough 15 12 Pruritus 15 13 Chills 14 Myalgia 12 10 Alopecia 10 Peripheral edema 10 aIncludes PTs of insomnia, initial insomnia, and poor quality sleep. Rash was reported in 9% and 7% of patients receiving eltrombopag and placebo, respectively. In the two controlled clinical trials in patients with chronic hepatitis C, hyperbilirubinemia was reported in 8% of patients receiving eltrombopag compared with 3% for placebo. Total bilirubin greater than or equal to 1.5 ULN was reported in 76% and 50% of patients receiving eltrombopag and placebo, respectively. ALT or AST greater than or equal to x ULN was reported in 34% and 38% of patients for eltrombopag and placebo, respectively. In the two controlled clinical trials in patients with chronic hepatitis C, cataracts developed or worsened in 8% of patients treated with eltrombopag and 5% of patients treated with placebo. The safety of eltrombopag was also assessed in all patients treated with eltrombopag in the two controlled trials, including patients who initially received eltrombopag in the pre-antiviral treatment phase of the trial and were later randomized to the placebo arm (N 1520 eltrombopag-treated patients). Hepatic failure was reported in 0.8% of eltrombopag-treated patients and 0.4% of placebo-treated patients. Severe Aplastic Anemia Refractory Severe Aplastic Anemia In the single-arm, open-label trial, 43 patients with refractory severe aplastic anemia received eltrombopag. Eleven patients (26%) were treated for greater than months and patients (16%) were treated for greater than year. The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache. Table 13. Adverse Reactions (>= 10%) From One Open-label Trial in Adults With Refractory Severe Aplastic Anemia Adverse reaction Eltrombopag = 43 (%) Nausea 33 Fatigue 28 Cough 23 Diarrhea 21 Headache 21 Pain in extremity 19 Pyrexia 14 Dizziness 14 Oropharyngeal pain 14 Abdominal pain 12 Muscle spasms 12 Transaminases increased 12 Arthralgia 12 Rhinorrhea 12 Rash and hyperbilirubinemia were reported in 7% of patients; cataract was reported in 2% of patients. In this trial, concurrent ALT or AST greater than x ULN with total bilirubin greater than 1.5 ULN were reported in 5% of patients. Total bilirubin greater than 1.5 ULN occurred in 14% of patients. In this trial, patients had bone marrow aspirates evaluated for cytogenetic abnormalities. Eight patients had new cytogenetic abnormality reported on therapy, including patients who had complex changes in chromosome 7. 6.2 Postmarketing Experience. The following adverse reactions have been identified during post approval use of eltrombopag. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate the frequency or establish causal relationship to drug exposure. Skin and Subcutaneous Tissue Disorders:Skin discoloration, including hyperpigmentation and skin yellowing. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Eltrombopag is TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. 12.2 Pharmacodynamics. In clinical trials, treatment with eltrombopag resulted in dose-dependent increases in platelet counts following repeated (daily) dosing. The increase in platelet counts reached maximum approximately two weeks after the initiation of dosing, and returned to baseline within approximately two weeks after the last dose of eltrombopag. Cardiac Electrophysiology At doses up to 150 mg (the maximum recommended dose) daily for days, eltrombopag did not prolong the QT/QTc interval to any relevant extent. 12.3 Pharmacokinetics. Eltrombopag demonstrated dose-proportional increase in exposure between doses of 50 to 150 mg/day in healthy adult subjects. Eltrombopag AUC was approximately 1.7-fold higher in patients with persistent or chronic ITP and approximately 2.8-fold higher in patients with HCV compared to healthy subjects. Steady-state was achieved after approximately week of once daily treatment, with geometric mean accumulation ratio of 1.56 (90% confidence interval 1.20, 1.63) at 75 mg/day. Eltrombopag for oral suspension delivered 22% higher plasma AUC 0-INFthan the tablet formulation. Absorption Eltrombopag is absorbed with peak concentration occurring to hours after oral administration. Oral absorption of drug-related material following administration of single 75 mg solution dose was estimated to be at least 52%. Effect of Food standard high-fat breakfast (876 calories, 52 fat, 71 carbohydrate, 34 protein, and 427 mg calcium) significantly decreased plasma eltrombopag AUC 0-INFby approximately 59% and maxby 65% and delayed maxby hour. The decrease in exposure is primarily due to the high calcium content. meal low in calcium (<= 50 mg calcium) did not significantly impact plasma eltrombopag exposure, regardless of calorie and fat content. The effect of administration of single 25 mg dose of eltrombopag for oral suspension with high-calcium, moderate-fat, moderate calorie meal on AUC 0-INFand maxin healthy adult subjects is presented in Table 14. Table 14. Effect on Plasma Eltrombopag Pharmacokinetic Parameters After Administration of Single 25 mg Dose of Eltrombopag for Oral Suspension With High Calcium Meal ain Healthy Adult Subjects Timing of eltrombopag for oral suspension doseMean (90% CI) reduction in plasma eltrombopag AUC 0-INF Mean (90% CI) reduction in plasma eltrombopag max With high-calcium, moderate-fat, moderate-calorie meal 75% (71%, 88%) 79% (76%, 82%) hours after the high-calcium, moderate-fat, moderate-calorie meal 47% (40%, 53%) 48% (40%, 54%) hours before the high-calcium, moderate-fat, moderate-calorie meal 20% (9%, 29%) 14% (2%, 25%) a372 calories, g fat, and 448 mg calcium. Distribution The concentration of eltrombopag in blood cells is approximately 50% to 79% of plasma concentrations based on radiolabel study. In vitrostudies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%). Eltrombopag is substrate of BCRP, but is not substrate for P-glycoprotein (P-gp) or OATP1B1. Elimination The plasma elimination half-life of eltrombopag is approximately 21 to 32 hours in healthy subjects and 26 to 35 hours in patients with ITP. Metabolism:Absorbed eltrombopag is extensively metabolized, predominantly through pathways, including cleavage, oxidation, and conjugation with glucuronic acid, glutathione, or cysteine. In vitrostudies suggest that CYP1A2 and CYP2C8 are responsible for the oxidative metabolism of eltrombopag. UGT1A1 and UGT1A3 are responsible for the glucuronidation of eltrombopag. Excretion: The predominant route of eltrombopag excretion is via feces (59%), and 31% of the dose is found in the urine. Unchanged eltrombopag in feces accounts for approximately 20% of the dose; unchanged eltrombopag is not detectable in urine. Specific Populations Ethnicity Eltrombopag concentrations in East-/Southeast-Asian ancestry patients with ITP or chronic hepatitis C, were 50% to 55% higher compared with non-Asian subjects [see Dosage and Administration (2.1, 2.3)]. Eltrombopag exposure in healthy African-American subjects was approximately 40% higher than that observed in Caucasian subjects in one clinical pharmacology trial and similar in three other clinical pharmacology trials. The effect of African-American ethnicity on exposure and related safety and efficacy of eltrombopag has not been established. Hepatic Impairment Following single dose of eltrombopag (50 mg), plasma eltrombopag AUC 0-INFwas 41% higher in patients with mild hepatic impairment (Child-Pugh class A) compared with subjects with normal hepatic function. Plasma eltrombopag AUC 0-INFwas approximately 2-fold higher in patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) compared with subjects with normal hepatic function. The half-life of eltrombopag was prolonged 2-fold in these patients. This clinical trial did not evaluate protein-binding effects. Chronic Liver Disease Following repeat doses of eltrombopag in patients with thrombocytopenia and with chronic liver disease, mild hepatic impairment resulted in an 87% to 110% higher plasma eltrombopag AUC (0-)and moderate hepatic impairment resulted in approximately 141% to 240% higher plasma eltrombopag AUC (0-)values compared with patients with normal hepatic function. The half-life of eltrombopag was prolonged 3-fold in patients with mild hepatic impairment and 4-fold in patients with moderate hepatic impairment. This clinical trial did not evaluate protein-binding effects. Chronic Hepatitis Patients with chronic hepatitis treated with eltrombopag had higher plasma AUC( 0-) values as compared with healthy subjects, and AUC( 0-) increased with increasing Child-Pugh score. Patients with chronic hepatitis and mild hepatic impairment had approximately 100% to 144% higher plasma AUC( 0-) compared with healthy subjects. This clinical trial did not evaluate protein-binding effects. Renal Impairment Following single dose of eltrombopag (50 mg), the average total plasma eltrombopag AUC 0-INFwas 32% to 36% lower in subjects with mild (estimated creatinine clearance (CLCr) by Cockcroft-Gault equation: 50 to 80 mL/min), to moderate (CLCr of 30 to 49 mL/min) renal impairment and 60% lower in subjects with severe (CLCr less than 30 mL/min) renal impairment compared with healthy subjects. The effect of renal impairment on unbound (active) eltrombopag exposure has not been assessed. Pediatric Patients The pharmacokinetics of eltrombopag have been evaluated in 168 pediatric patients year and older with ITP dosed once daily in two trials. Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight. East-/Southeast-Asian pediatric patients with ITP had approximately 43% higher plasma eltrombopag AUC (0-)values as compared with non-Asian patients. Plasma eltrombopag AUC (0-)and maxin pediatric patients aged 12 to 17 years was similar to that observed in adults. The pharmacokinetic parameters of eltrombopag in pediatric patients with ITP are shown in Table 15. Table 15. Geometric Mean (95% CI) Steady-state Plasma Eltrombopag Pharmacokinetic Parameters ain Patients With ITP (Normalized to Once-daily 50 mg Dose) AgeC max b(mcg/mL)AUC (0- )b(mcg.hr/mL) Adults (n 108) 7.03 (6.44, 7.68) 101 (91.4, 113) 12 to 17 years (n 62) 6.80 (6.17, 7.50) 103 (91.1, 116) to 11 years (n 68) 10.3 (9.42, 11.2) 153 (137, 170) to years (n 38) 11.6 (10.4, 12.9) 162 (139, 187) aPK parameters presented as geometric mean (95% CI). bBased on population PK post-hoc estimates. Drug Interaction Studies Clinical Studies Effect of Drugs on Eltrombopag Effect of Polyvalent Cation-containing Antacids on Eltrombopag: The coadministration of single dose of eltrombopag (75 mg) with polyvalent cation-containing antacid (1,524 mg aluminum hydroxide, 1,425 mg magnesium carbonate, and sodium alginate) decreased plasma eltrombopag AUC 0-INFand maxby approximately 70%. The contribution of sodium alginate to this interaction is not known. Effect of HIV Protease Inhibitors on Eltrombopag: The coadministration of repeat-dose lopinavir 400 mg/ritonavir 100 mg (twice daily) with single dose of eltrombopag (100 mg) decreased plasma eltrombopag AUC 0-INFby 17%. Effect of HCV Protease Inhibitors on Eltrombopag: The coadministration of repeat-dose telaprevir (750 mg every hours) or boceprevir (800 mg every hours) with single dose of eltrombopag (200 mg) to healthy adult subjects in clinical trial did not alter plasma eltrombopag AUC 0-INFor maxto significant extent. Effect of Cyclosporine on Eltrombopag: The coadministration of single dose of eltrombopag (50 mg) with single dose of an OATP and BCRP inhibitor cyclosporine (200 mg or 600 mg) decreased plasma eltrombopag AUC 0-INFby 18% to 24% and maxby 25% to 39%. Effect of Pegylated Interferon alfa-2a Ribavirin and Pegylated Interferon alfa-2b Ribavirin on Eltrombopag: The presence of pegylated interferon alfa ribavirin therapy did not significantly affect the clearance of eltrombopag. Effect of Eltrombopag on Other Drugs Effect of Eltrombopag on Cytochrome P450 Enzymes Substrates: The coadministration of multiple doses of eltrombopag (75 mg once daily for days) did not result in the inhibition or induction of the metabolism of combination of probe substrates for CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP2C9 (flurbiprofen), or CYP3A4 (midazolam) in humans. Effect of Eltrombopag on Rosuvastatin: The coadministration of multiple doses of eltrombopag (75 mg once daily for days) with single dose of rosuvastatin (OATP1B1 and BCRP substrate; 10 mg) increased plasma rosuvastatin AUC 0-INFby 55% and maxby 103%. Effect of Eltrombopag on HCV Protease Inhibitors: The coadministration of repeat-dose telaprevir (750 mg every hours) or boceprevir (800 mg every hours) with single dose of eltrombopag (200 mg) to healthy adult subjects in clinical trial did not alter plasma telaprevir or boceprevir AUC 0-INFor maxto significant extent. In vitro Studies Eltrombopag Effect on Metabolic Enzymes Eltrombopag has demonstrated the potential to inhibit CYP2C8, CYP2C9, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15. Eltrombopag Effect on Transporters Eltrombopag has demonstrated the potential to inhibit OATP1B1 and BCRP. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Persistent or Chronic ITP. Adults:The efficacy and safety of eltrombopag in adult patients with persistent or chronic ITP were evaluated in three randomized, double-blind, placebo-controlled trials and in an open-label extension trial. In Study TRA100773B and Study TRA100773A (referred to as Study 773B and Study 773A, respectively [NCT00102739]), patients who had completed at least one prior ITP therapy and who had platelet count less than 30 10 9/L were randomized to receive either eltrombopag or placebo daily for up to weeks, followed by weeks off therapy. During the trials, eltrombopag or placebo was discontinued if the platelet count exceeded 200 10 9/L. The median age of the patients was 50 years and 60% were female. Approximately 70% of the patients had received at least prior ITP therapies (predominantly corticosteroids, immunoglobulins, rituximab, cytotoxic therapies, danazol, and azathioprine) and 40% of the patients had undergone splenectomy. The median baseline platelet counts (approximately 18 10 9/L) were similar among all treatment groups. Study 773B randomized 114 patients (2:1) to eltrombopag 50 mg or placebo. Of 60 patients with documented time since diagnosis, approximately 17% met the definition of persistent ITP with time since diagnosis of 3-12 months. Study 773A randomized 117 patients (1:1:1:1) among placebo or of dose regimens of eltrombopag, 30 mg, 50 mg, or 75 mg each administered daily. Of 51 patients with documented time since diagnosis, approximately 14% met the definition of persistent ITP. The efficacy of eltrombopag in this trial was evaluated by response rate, defined as shift from baseline platelet count of less than 30 10 9/L to greater than or equal to 50 10 9/L at any time during the treatment period (Table 16). Table 16. Studies 773B and 773A: Platelet Count Response (>= 50 10 9/L) Rates in Adults with Persistent or Chronic Immune Thrombocytopenia Thrombocytopenia StudyEltrombopag50 mg DailyPlacebo773B 43/73 (59%) 6/37 (16%) 773A 19/27 (70%) 3/27 (11%) ap-value 0.001 for eltrombopag versus placebo. The platelet count response to eltrombopag was similar among patients who had or had not undergone splenectomy. In general, increases in platelet counts were detected week following initiation of eltrombopag and the maximum response was observed after weeks of therapy. In the placebo and 50 mg-dose groups of eltrombopag, the trial drug was discontinued due to an increase in platelet counts to greater than 200 10 9/L in 3% and 27% of the patients, respectively. The median duration of treatment with the 50 mg dose of eltrombopag was 43 days in Study 773B and 42 days in Study 773A. Of patients who underwent hemostatic challenges, additional ITP medications were required in of placebo group patients and of patients treated with eltrombopag. Surgical procedures accounted for most of the hemostatic challenges. Hemorrhage requiring transfusion occurred in one placebo group patient and no patients treated with eltrombopag. In the RAISE study (NCT00370331), 197 patients were randomized (2:1) to receive either eltrombopag 50 mg once daily (n 135) or placebo (n 62) for months, during which time the dose of eltrombopag could be adjusted based on individual platelet counts. Of 145 patients with documented time since diagnosis, 19% met the definition of persistent ITP. Patients were allowed to taper or discontinue concomitant ITP medications after being treated with eltrombopag for weeks. Patients were permitted to receive rescue treatments at any time during the trial as clinically indicated. The median ages of the patients treated with eltrombopag and placebo were 47 years and 52.5 years, respectively. Approximately half of the patients treated with eltrombopag and placebo (47% and 50%, respectively) were receiving concomitant ITP medication (predominantly corticosteroids) at randomization and had baseline platelet counts less than or equal to 15 10 9/L (50% and 48%, respectively). similar percentage of patients treated with eltrombopag and placebo (37% and 34%, respectively) had prior splenectomy. The efficacy of eltrombopag in this trial was evaluated by the odds of achieving platelet count greater than or equal to 50 10 9/L and less than or equal to 400 10 9/L for patients receiving eltrombopag relative to placebo and was based on patient response profiles throughout the 6-month treatment period. In 134 patients who completed 26 weeks of treatment, sustained platelet response (platelet count greater than or equal to 50 10 9/L and less than or equal to 400 10 9/L for out of the last weeks of the 26-week treatment period in the absence of rescue medication at any time) was achieved by 60% of patients treated with eltrombopag, compared with 10% of patients treated with placebo (splenectomized patients: eltrombopag 51%, placebo 8%; non-splenectomized patients: eltrombopag 66%, placebo 11%). The proportion of responders in the group of patients treated with eltrombopag was between 37% and 56% compared with 7% and 19% in the placebo treatment group for all on-therapy visits. Patients treated with eltrombopag were significantly more likely to achieve platelet count between 50 109/L and 400 10 9/L during the entire 6-month treatment period compared with those patients treated with placebo. Outcomes of treatment are presented in Table 17 for all patients enrolled in the trial. Table 17. RAISE: Outcomes of Treatment in Adults With Persistent or Chronic Immune Thrombocytopenia OutcomeEltrombopagn 135Placebon 62Mean number of weeks with platelet counts >= 50 10 9/L 11.3 2.4 Requiring rescue therapy, (%) 24 (18) 25 (40) Among 94 patients receiving other ITP therapy at baseline, 37 (59%) of 63 patients treated with eltrombopag and 10 (32%) of 31 patients in the placebo group discontinued concomitant therapy at some time during the trial. In the EXTEND study (NCT00351468), patients who completed any prior clinical trial with eltrombopag were enrolled in an open-label, single-arm trial in which attempts were made to decrease the dose or eliminate the need for any concomitant ITP medications. eltrombopag was administered to 302 patients in EXTEND; 218 patients completed year, 180 patients completed years, 107 patients completed years, 75 patients completed years, 34 patients completed years, and 18 patients completed years of therapy. The median baseline platelet count was 19 109/L prior to administration of eltrombopag. Median platelet counts at 1, 2, 3, 4, 5, 6, and years on study were 85 10 9/L, 85 10 9/L, 105 10 9/L, 64 10 9/L, 75 10 9/L, 119 10 9/L, and 76 10 9/L, respectively. Pediatric Patients: The efficacy and safety of eltrombopag in pediatric patients year and older with persistent or chronic ITP were evaluated in two double-blind, placebo-controlled trials. The trials differed in time since ITP diagnosis: at least months versus at least 12 months. During the trials, doses could be increased every weeks to maximum of 75 mg once daily. The dose of eltrombopag was reduced if the platelet count exceeded 200 10 9/L and interrupted and reduced if it exceeded 400 10 9/L. In the PETIT2 study (NCT01520909), patients refractory or relapsed to at least one prior ITP therapy with platelet count less than 30 109/L (n 92) were stratified by age and randomized (2:1) to eltrombopag (n 63) or placebo (n 29). The starting dose for patients aged to 17 years was 50 mg once daily for those at least 27 kg and 37.5 mg once daily for those less than 27 kg, administered as oral tablets. reduced dose of 25 mg once daily was used for East-/Southeast-Asian patients aged to 17 years regardless of weight. The starting dose for patients aged to years was 1.2 mg/kg once daily (0.8 mg/kg once daily for East-/Southeast-Asian patients) administered as oral suspension. The 13-week, randomized, double-blind period was followed by 24-week, open-label period where patients from both arms were eligible to receive eltrombopag. The median age of the patients was years and 48% were female. Approximately 62% of patients had baseline platelet count less than or equal to 15 10 9/L, characteristic that was similar between treatment arms. The percentage of patients with at least prior ITP therapies (predominantly corticosteroids and immunoglobulins) was 73% in the group treated with eltrombopag and 90% in the group treated with placebo. Four patients in the group treated with eltrombopag had undergone splenectomy. The efficacy of eltrombopag in this trial was evaluated by the proportion of subjects on eltrombopag achieving platelet counts >= 50 10 9/L (in the absence of rescue therapy) for at least out of weeks between Weeks to 12 of the randomized, double-blind period (Table 18). Table 18. PETIT2: Platelet Count Response (>= 50 10 9/L Without Rescue) for out of Weeks (between Weeks to 12) Overall and by Age Cohort in Pediatric Patients Year and Older With Chronic Immune Thrombocytopenia Age cohortEltrombopagPlaceboOverall 12 to 17 years to 11 years to years 26/63 (41%) 10/24 (42%) 11/25 (44%) 5/14 (36%) 1/29 (3%) 1/10 (10%) 0/13 (0%) 0/6 (0%) ap-value < 0.001 for eltrombopag versus placebo. More pediatric patients treated with eltrombopag (75%) compared with placebo (21%) had at least one platelet count greater than or equal to 50 10 9/L during the first 12 weeks of randomized treatment in absence of rescue therapy. Fewer pediatric patients treated with eltrombopag required rescue treatment during the randomized, double-blind period compared with placebo-treated patients (19% [12/63] versus 24% [7/29]). In the patients who achieved platelet response (>= 50 10 9/L without rescue) for out of weeks (between weeks to 12), 62% (16/26) had an initial response in the first weeks after starting eltrombopag. Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the trial. Among 15 patients receiving other ITP therapy at baseline, 53% (8/15) reduced (n 1) or discontinued (n 7) concomitant therapy, mainly corticosteroids, without needing rescue therapy. In the PETIT study (NCT00908037), patients refractory or relapsed to at least one prior ITP therapy with platelet count less than 30 10 9/L (n 67) were stratified by age and randomized (2:1) to eltrombopag (n 45) or placebo (n 22). Approximately 15% of patients met the definition of persistent ITP. The starting dose for patients aged 12 to 17 years was 37.5 mg once daily regardless of weight or race. The starting dose for patients aged to 11 years was 50 mg once daily for those greater than or equal to 27 kg and 25 mg once daily for those less than 27 kg, administered as oral tablets. Reduced doses of 25 mg (for those greater than or equal to 27 kg) and 12.5 mg (for those less than 27 kg), each once daily, were used for East-/Southeast-Asian patients in this age range. The starting dose for patients aged to years was 1.5 mg/kg once daily (0.8 mg/kg once daily for East-/Southeast-Asian patients) administered as oral suspension. The 7-week, randomized, double-blind period was followed by an open-label period of up to 24 weeks where patients from both arms were eligible to receive eltrombopag. The median age of the patients was 10 years and 60% were female. Approximately 51% of patients had baseline platelet count less than or equal to 15 10 9/L. The percentage of patients with at least prior ITP therapies (predominantly corticosteroids and immunoglobulins) was 84% in the group treated with eltrombopag and 86% in the group treated with placebo. Five patients in the group treated with eltrombopag had undergone splenectomy. The efficacy of eltrombopag in this trial was evaluated by the proportion of patients achieving platelet counts greater than or equal to 50 10 9/L (in absence of rescue therapy) at least once between Weeks and of the randomized, double-blind period (Table 19). Platelet response to eltrombopag was consistent across the age cohorts. Table 19. PETIT: Platelet Count Response (>= 50 10 9/L Without Rescue) Rates in Pediatric Patients Year and Older With Persistent or Chronic Immune Thrombocytopenia EltrombopagPlaceboOverall28/45 (62%) 7/22 (32%) 12 to 17 years 10/16 (62%) 0/8 (0%) to 11 years 12/19 (63%) 3/9 (33%) to years 6/10 (60%) 4/5 (80%) ap-value 0.011 for eltrombopag versus placebo. Fewer pediatric patients treated with eltrombopag required rescue treatment during the randomized, double-blind period compared with placebo-treated patients (13% [6/45] versus 50% [11/22]). Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the trial. Among 13 patients receiving other ITP therapy at baseline, 46% (6/13) reduced (n 3) or discontinued (n 3) concomitant therapy, mainly corticosteroids, without needing rescue therapy. 14.2 Chronic Hepatitis C-Associated Thrombocytopenia. The efficacy and safety of eltrombopag for the treatment of thrombocytopenia in adult patients with chronic hepatitis were evaluated in two randomized, double-blind, placebo-controlled trials. The ENABLE1 study (NCT00516321) utilized peginterferon alfa-2a (PEGASYS (R)) plus ribavirin for antiviral treatment and the ENABLE2 study (NCT00529568) utilized peginterferon alfa-2b (PEGINTRON (R)) plus ribavirin. In both trials, patients with platelet count of less than 75 10 9/L were enrolled and stratified by platelet count, screening HCV RNA, and HCV genotype. Patients were excluded if they had evidence of decompensated liver disease with Child-Pugh score greater than (class and C), history of ascites, or hepatic encephalopathy. The median age of the patients in both trials was 52 years, 63% were male, and 74% were Caucasian. Sixty-nine percent of patients had HCV genotypes 1, 4, 6, with the remainder genotypes and 3. Approximately 30% of patients had been previously treated with interferon and ribavirin. The majority of patients (90%) had bridging fibrosis and cirrhosis, as indicated by noninvasive testing. similar proportion (95%) of patients in both treatment groups had Child-Pugh class (score to 6) at baseline. similar proportion of patients (2%) in both treatment groups had baseline international normalized ratio (INR) greater than 1.7. Median baseline platelet counts (approximately 60 10 9/L) were similar in both treatment groups. The trials consisted of phases a preantiviral treatment phase and an antiviral treatment phase. In the pre-antiviral treatment phase, patients received open-label eltrombopag to increase the platelet count to threshold of greater than or equal to 90 10 9/L for ENABLE1 and greater than or equal to 100 10 9/L for ENABLE2. Eltrombopag was administered at an initial dose of 25 mg once daily for weeks and increased in 25 mg increments over 2-to 3-week periods to achieve the optimal platelet count to initiate antiviral therapy. The maximal time patients could receive open-label eltrombopag was weeks. If threshold platelet counts were achieved, patients were randomized (2:1) to the same dose of eltrombopag at the end of the pre-treatment phase or to placebo. Eltrombopag was administered in combination with pegylated interferon and ribavirin per their respective prescribing information for up to 48 weeks. The efficacy of eltrombopag for both trials was evaluated by sustained virologic response (SVR) defined as the percentage of patients with undetectable HCV-RNA at 24 weeks after completion of antiviral treatment. The median time to achieve the target platelet count greater than or equal to 90 10 9/L was approximately weeks. Ninety-five percent of patients were able to initiate antiviral therapy. In both trials, significantly greater proportion of patients treated with eltrombopag achieved SVR (see Table 20). The improvement in the proportion of patients who achieved SVR was consistent across subgroups based on baseline platelet count (less than 50 10 9/L versus greater than or equal to 50 10 9/L). In patients with high baseline viral loads (greater than or equal to 800,000), the SVR rate was 18% (82/452) for eltrombopag versus 8% (20/239) for placebo. Table 20. ENABLE1 and ENABLE2: Sustained Virologic Response (SVR) in Adults With Chronic Hepatitis Pre-antiviral treatment phase ENABLE1 ENABLE2 n 715 = 805 Patients who achieved target platelet counts and initiated antiviral therapy 95% 94% Antiviral treatment phase Eltrombopag = 450 Placebo = 232 Eltrombopag = 506 Placebo = 253 Overall SVR HCV genotype 2,3 HCV genotype 1,4,6 23 35 18 14 24 10 19 34 13 13 25 Abbreviation: HCV, hepatitis virus. aEltrombopag given in combination with peginterferon alfa-2a (180 mcg once weekly for 48 weeks for genotypes 1/4/6; 24 weeks for genotype or 3) plus ribavirin (800 to 1,200 mg daily in divided doses orally). bEltrombopag given in combination with peginterferon alfa-2b (1.5 mcg/kg once weekly for 48 weeks for genotypes 1/4/6; 24 weeks for genotype or 3) plus ribavirin (800 to 1,400 mg daily in divided doses orally). cTarget platelet count was >= 90 10 9/L for ENABLE1 and >= 100 10 9/L for ENABLE2. p-value 0.05 for eltrombopag versus placebo. The majority of patients treated with eltrombopag (76%) maintained platelet count greater than or equal to 50 10 9/L compared with 19% for placebo. greater proportion of patients on eltrombopag did not require any antiviral dose reduction as compared with placebo (45% versus 27%). 14.3 Severe Aplastic Anemia. Refractory Severe Aplastic Anemia Eltrombopag was studied in single-arm, single-center, open-label trial (Study ETB115AUS28T, referred to as Study US28T [NCT00922883]) in 43 patients with severe aplastic anemia who had an insufficient response to at least one prior immunosuppressive therapy and who had platelet count less than or equal to 30 10 9/L. Eltrombopag was administered at an initial dose of 50 mg once daily for weeks and increased over 2-week periods up to maximum dose of 150 mg once daily. The efficacy of eltrombopag in the study was evaluated by the hematologic response assessed after 12 weeks of treatment. Hematologic response was defined as meeting or more of the following criteria: 1) platelet count increases to 20 10 9/L above baseline, or stable platelet counts with transfusion independence for minimum of weeks; 2) hemoglobin increase by greater than 1.5 g/dL, or reduction in greater than or equal to units of red blood cell (RBC) transfusions for consecutive weeks; 3) ANC increase of 100% or an ANC increase greater than 0.5 10 9/L. Eltrombopag was discontinued after 16 weeks if no hematologic response was observed. Patients who responded continued therapy in an extension phase of the trial. The treated population had median age of 45 years (range, 17 to 77 years) and 56% were male. At baseline, the median platelet count was 20 10 9/L, hemoglobin was 8.4 g/dL, ANC was 0.58 10 9/L, and absolute reticulocyte count was 24.3 10 9/L. Eighty-six percent of patients were red blood cell (RBC) transfusion dependent and 91% were platelet transfusion dependent. The majority of patients (84%) received at least prior immunosuppressive therapies. Three patients had cytogenetic abnormalities at baseline. Table 23 presents the efficacy results. Table 23. Study US28T: Hematologic Response in Patients With Refractory Severe Aplastic Anemia Outcome Eltrombopag = 43 Response rate a, (%) 95% CI (%) 17 (40) (25, 56) Median of duration of response in months (95% CI) NR b(3.0, NR b) aIncludes single-and multi-lineage. bNR not reached due to few events (relapsed). In the 17 responders, the platelet transfusion-free period ranged from to 1096 days with median of 200 days, and the RBC transfusion-free period ranged from 15 to 1082 days with median of 208 days. In the extension phase, patients achieved multi-lineage response; of these patients subsequently tapered off treatment with eltrombopag and maintained the response (median follow up: 8.1 months, range, 7.2 to 10.6 months).

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Take eltrombopag for oral suspension without meal or with meal low in calcium (<= 50 mg). Take eltrombopag for oral suspension at least hours before or hours after any medications or products containing polyvalent cations, such as antacids, calcium-rich foods, and mineral supplements. 2.4, 7.1, 12.3) Persistent or Chronic ITP:Initiate eltrombopag for oral suspension at 50 mg once daily for most adult and pediatric patients years and older, and at 25 mg once daily for pediatric patients aged to years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 10 9/L. Do not exceed 75 mg per day. 2.1, 8.6, 8.7) Chronic Hepatitis C-associated Thrombocytopenia:Initiate eltrombopag for oral suspension at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed daily dose of 100 mg. 2.2) Refractory Severe Aplastic Anemia:Initiate eltrombopag for oral suspension at 50 mg once daily. Reduce initial dose in patients with hepatic impairment or patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than 50 10 9/L. Do not exceed 150 mg per day. 2.3, 8.6, 8.7) Take eltrombopag for oral suspension without meal or with meal low in calcium (<= 50 mg). Take eltrombopag for oral suspension at least hours before or hours after any medications or products containing polyvalent cations, such as antacids, calcium-rich foods, and mineral supplements. 2.4, 7.1, 12.3) Persistent or Chronic ITP:Initiate eltrombopag for oral suspension at 50 mg once daily for most adult and pediatric patients years and older, and at 25 mg once daily for pediatric patients aged to years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 10 9/L. Do not exceed 75 mg per day. 2.1, 8.6, 8.7) Chronic Hepatitis C-associated Thrombocytopenia:Initiate eltrombopag for oral suspension at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed daily dose of 100 mg. 2.2) Refractory Severe Aplastic Anemia:Initiate eltrombopag for oral suspension at 50 mg once daily. Reduce initial dose in patients with hepatic impairment or patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than 50 10 9/L. Do not exceed 150 mg per day. 2.3, 8.6, 8.7) 2.1 Persistent or Chronic Immune Thrombocytopenia. Use the lowest dose of eltrombopag for oral suspension to achieve and maintain platelet count greater than or equal to 50 10 9/L as necessary to reduce the risk for bleeding. Dose adjustments are based upon the platelet count response. Do not use eltrombopag for oral suspension to normalize platelet counts [see Warnings and Precautions (5.4)]. In clinical trials, platelet counts generally increased within to weeks after starting eltrombopag for oral suspension and decreased within to weeks after discontinuing eltrombopag for oral suspension [see Clinical Studies (14.1)] Initial Dose Regimen: Adult and Pediatric Patients Years and Older with ITP: Initiate eltrombopag for oral suspension at dose of 50 mg once daily, except in patients who are of East-/Southeast-Asian ancestry or who have mild to severe hepatic impairment (Child-Pugh class A, B, C). For patients of East-/Southeast-Asian ancestry with ITP, initiate eltrombopag for oral suspension at reduced dose of 25 mg once daily [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. For patients with ITP and mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, C), initiate eltrombopag for oral suspension at reduced dose of 25 mg once daily [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. For patients of East-/Southeast-Asian ancestry with ITP and hepatic impairment (Child-Pugh class A, B, C), consider initiating eltrombopag for oral suspension at reduced dose of 12.5 mg once daily seeClinical Pharmacology (12.3)] Pediatric Patients with ITP Aged to Years:Initiate eltrombopag for oral suspension at dose of 25 mg once daily [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. Monitoring and Dose Adjustment:After initiating eltrombopag for oral suspension, adjust the dose to achieve and maintain platelet count greater than or equal to 50 10 9/L as necessary to reduce the risk for bleeding. Do not exceed dose of 75 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with eltrombopag for oral suspension and modify the dosage regimen of eltrombopag for oral suspension based on platelet counts as outlined in Table 1. During therapy with eltrombopag for oral suspension, assess complete blood counts (CBCs) with differentials, including platelet counts, weekly until stable platelet count has been achieved. Obtain CBCs with differentials, including platelet counts, monthly thereafter. When switching between the oral suspension and tablet, assess platelet counts weekly for weeks, and then follow standard monthly monitoring. Table 1. Dose Adjustments of Eltrombopag for Oral Suspension in Patients With Persistent or Chronic Immune Thrombocytopenia Platelet count resultDose adjustment or response< 50 10 9/L following at least weeks of eltrombopag for oral suspension Increase daily dose by 25 mg to maximum of 75 mg/day. For patients taking 12.5 mg once daily, increase the dose to 25 mg daily before increasing the dose amount by 25 mg. >= 200 10 9/L to <= 400 10 9/L at any time Decrease the daily dose by 25 mg. Wait weeks to assess the effects of this and any subsequent dose adjustments. For patients taking 25 mg once daily, decrease the dose to 12.5 mg once daily. 400 10 9/L Stop eltrombopag for oral suspension; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is 150 10 9/L, reinitiate therapy at daily dose reduced by 25 mg. For patients taking 25 mg once daily, reinitiate therapy at daily dose of 12.5 mg. 400 10 9/L after weeks of therapy at lowest dose of eltrombopag for oral suspension Discontinue eltrombopag for oral suspension. In patients with ITP and hepatic impairment (Child-Pugh class A, B, C), after initiating eltrombopag for oral suspension or after any subsequent dosing increase, wait weeks before increasing the dose. Modify the dosage regimen of concomitant ITP medications, as medically appropriate, to avoid excessive increases in platelet counts during therapy with eltrombopag for oral suspension. Do not administer more than one dose of eltrombopag for oral suspension within any 24-hour period. Discontinuation:Discontinue eltrombopag for oral suspension if the platelet count does not increase to level sufficient to avoid clinically important bleeding after weeks of therapy with eltrombopag for oral suspension at the maximum daily dose of 75 mg. Excessive platelet count responses, as outlined in Table 1, or important liver test abnormalities also necessitate discontinuation of eltrombopag for oral suspension [see Warnings and Precautions (5.2)]. Obtain CBCs with differentials, including platelet counts, weekly for at least weeks following discontinuation of eltrombopag for oral suspension. 2.2 Chronic Hepatitis C-Associated Thrombocytopenia. Use the lowest dose of eltrombopag for oral suspension to achieve and maintain platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin. Dose adjustments are based upon the platelet count response. Do not use eltrombopag for oral suspension to normalize platelet counts [see Warnings and Precautions 5.4)] In clinical trials, platelet counts generally began to rise within the first week of treatment with eltrombopag for oral suspension [see Clinical Studies 14.2)]. Initial Dose Regimen: Initiate eltrombopag for oral suspension at dose of 25 mg once daily. Monitoring and Dose Adjustment:Adjust the dose of eltrombopag for oral suspension in 25 mg increments every weeks as necessary to achieve the target platelet count required to initiate antiviral therapy. Monitor platelet counts every week prior to starting antiviral therapy. During antiviral therapy, adjust the dose of eltrombopag for oral suspension to avoid dose reductions of peginterferon. Monitor CBCs with differentials, including platelet counts, weekly during antiviral therapy until stable platelet count is achieved. Monitor platelet counts monthly thereafter. Do not exceed dose of 100 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with eltrombopag for oral suspension. For specific dosage instructions for peginterferon or ribavirin, refer to their respective prescribing information. Table 2. Dose Adjustments of Eltrombopag for Oral Suspension in Adults with Thrombocytopenia Due to Chronic Hepatitis Platelet count result Dose adjustment or response 50 10 9/L following at least weeks of eltrombopag for oral suspension Increase daily dose by 25 mg to maximum of 100 mg/day. >= 200 10 9/L to <= 400 10 9/L at any time Decrease the daily dose by 25 mg. Wait weeks to assess the effects of this and any subsequent dose adjustments. 400 10 9/L Stop eltrombopag for oral suspension; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is 150 10 9/L, reinitiate therapy at daily dose reduced by 25 mg. For patients taking 25 mg once daily, reinitiate therapy at daily dose of 12.5 mg. 400 10 9/L after weeks of therapy at lowest dose of eltrombopag for oral suspension Discontinue eltrombopag for oral suspension. Discontinuation:The prescribing information for pegylated interferon and ribavirin include recommendations for antiviral treatment discontinuation for treatment futility. Refer to pegylated interferon and ribavirin prescribing information for discontinuation recommendations for antiviral treatment futility. Eltrombopag for oral suspension should be discontinued when antiviral therapy is discontinued. Excessive platelet count responses, as outlined in Table 2, or important liver test abnormalities also necessitate discontinuation of eltrombopag for oral suspension [see Warnings and Precautions 5.2)]. 2.3 Severe Aplastic Anemia. Refractory Severe Aplastic Anemia Use the lowest dose of eltrombopag for oral suspension to achieve and maintain hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 150 mg, and may take up to 16 weeks after starting eltrombopag for oral suspension [see Clinical Studies 14.3)]. Initial Dose Regimen:Initiate eltrombopag for oral suspension at dose of 50 mg once daily. For patients with severe aplastic anemia of East-/Southeast-Asian ancestry or those with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, C), initiate eltrombopag for oral suspension at reduced dose of 25 mg once daily [see Use in Specific Populations 8.6, 8.7), Clinical Pharmacology 12.3)]. Monitoring and Dose Adjustment:Adjust the dose of eltrombopag for oral suspension in 50 mg increments every weeks as necessary to achieve the target platelet count greater than or equal to 50 10 9/L as necessary. Do not exceed dose of 150 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with eltrombopag for oral suspension and modify the dosage regimen of eltrombopag for oral suspension based on platelet counts as outlined in Table 7. Table 7. Dose Adjustments of Eltrombopag for Oral Suspension in Patients With Refractory Severe Aplastic Anemia Platelet count result Dose adjustment or response 50 10 9/L following at least weeks of eltrombopag for oral suspension Increase daily dose by 50 mg to maximum of 150 mg/day. For patients taking 25 mg once daily, increase the dose to 50 mg daily before increasing the dose amount by 50 mg. >= 200 10 9/L to <= 400 10 9/L at any time Decrease the daily dose by 50 mg. Wait weeks to assess the effects of this and any subsequent dose adjustments. 400 10 9/L Stop eltrombopag for oral suspension for week. Once the platelet count is 150 10 9/L, reinitiate therapy at dose reduced by 50 mg. 400 10 9/L after weeks of therapy at lowest dose of eltrombopag for oral suspension Discontinue eltrombopag for oral suspension. For patients who achieve tri-lineage response, including transfusion independence, lasting at least weeks: the dose of eltrombopag for oral suspension may be reduced by 50% [see Clinical Studies 14.3)]. If counts remain stable after weeks at the reduced dose, then discontinue eltrombopag for oral suspension and monitor blood counts. If platelet counts drop to less than 30 10 9/L, hemoglobin to less than g/dL, or absolute neutrophil count (ANC) to less than 0.5 10 9/L, eltrombopag for oral suspension may be reinitiated at the previous effective dose. Discontinuation:If no hematologic response has occurred after 16 weeks of therapy with eltrombopag for oral suspension, discontinue therapy. If new cytogenetic abnormalities are observed, consider discontinuation of eltrombopag for oral suspension [see Adverse Reactions 6.1)]. Excessive platelet count responses (as outlined in Table 7) or important liver test abnormalities also necessitate discontinuation of eltrombopag for oral suspension [see Warnings and Precautions 5.2)]. 2.4 Administration. Administration of Oral Suspension:Take eltrombopag for oral suspension without meal or with meal low in calcium (<= 50 mg). Take eltrombopag for oral suspension at least hours before or hours after other medications (e.g., antacids), calcium-rich foods (containing 50 mg calcium e.g., dairy products, calcium-fortified juices, and certain fruits and vegetables), or supplements containing polyvalent cations, such as iron, calcium, aluminum, magnesium, selenium, and zinc [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. Preparation of the Oral Suspension:Prior to use of the oral suspension, ensure patients or caregivers receive training on proper dosing, preparation, and administration of eltrombopag for oral suspension. Administer the oral suspension immediately after preparation. Discard any suspension not administered within 30 minutes after preparation. Prepare the suspension with water only. NOTE: Do not use hot water to prepare the suspension. For details on preparation and administration of the suspension, including the recommended duration of use of each oral dosing syringe, [see Instructions for Use]. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Prior to treatment, patients should fully understand and be informed of the following risks and considerations for eltrombopag for oral suspension: Risks Hepatotoxicity Therapy with eltrombopag for oral suspension may be associated with hepatobiliary laboratory abnormalities [see Warnings and Precautions (5.2)]. Advise patients with chronic hepatitis and cirrhosis that they may be at risk for hepatic decompensation when receiving eltrombopag for oral suspension with alfa interferon therapy [see Warnings and Precautions 5.1)]. Advise patients that they should report any of the following signs and symptoms of liver problems to their healthcare provider right away [see Warnings and Precautions (5.2)]. yellowing of the skin or the whites of the eyes (jaundice) unusual darkening of the urine unusual tiredness right upper stomach area pain confusion swelling of the stomach area (abdomen) Risk of Bleeding Upon Eltrombopag for Oral Suspension Discontinuation Advise patients that thrombocytopenia and risk of bleeding may reoccur upon discontinuing eltrombopag for oral suspension, particularly if eltrombopag for oral suspension is discontinued while the patient is on anticoagulants or antiplatelet agents. Advise patients that during therapy with eltrombopag for oral suspension, they should continue to avoid situations or medications that may increase the risk for bleeding. Thrombotic/Thromboembolic Complications Advise patients that too much eltrombopag for oral suspension may result in excessive platelet counts and risk for thrombotic/thromboembolic complications [see Warnings and Precautions (5.4)]. Cataracts Advise patients to have baseline ocular examination prior to administration of eltrombopag for oral suspension and be monitored for signs and symptoms of cataracts during therapy [see Warnings and Precautions (5.5)]. Drug Interactions Advise patients to take eltrombopag for oral suspension at least hours before or hours after calcium-rich foods, mineral supplements, and antacids which contain polyvalent cations, such as iron, calcium, aluminum, magnesium, selenium, and zinc [see Dosage and Administration (2.4), Drug Interactions (7.1)]. Lactation Advise women not to breastfeed during treatment with eltrombopag for oral suspension [see Use in Specific Populations (8.2)]. Administration of eltrombopag for oral suspensionFor patients with persistent or chronic ITP, therapy with eltrombopag for oral suspension is administered to achieve and maintain platelet count greater than or equal to 50 10 9/L as necessary to reduce the risk for bleeding [see Indications and Usage (1.1)]. For patients with chronic hepatitis C, therapy with eltrombopag for oral suspension is administered to achieve and maintain platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin [see Indications and Usage 1.2)]. Advise patients to take eltrombopag for oral suspension without meal or with meal low in calcium (<= 50 mg) and at least hours before or hours after other medications (e.g., antacids) and calcium-rich foods [see Dosage and Administration 2.4)]. Prior to use of the oral suspension, ensure patients or caregivers receive training on proper dosing, preparation, and administration [see Dosage and Administration (2.4)]. Inform patients or caregivers how many packets to administer to get the full dose [see Instructions for Use]. Inform patients or caregivers to use new oral dosing syringe to prepare each dose of eltrombopag for oral suspension see Instructions for Use]. The brand listed are the registered trademarks of their respective owners and are not trademarks of Annora Pharma Private Limited. Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854. By: Annora Pharma Pvt. Ltd. Sangareddy 502313, Telangana, India. Revised: 09/2024 Therapy with eltrombopag for oral suspension may be associated with hepatobiliary laboratory abnormalities [see Warnings and Precautions (5.2)]. Advise patients with chronic hepatitis and cirrhosis that they may be at risk for hepatic decompensation when receiving eltrombopag for oral suspension with alfa interferon therapy [see Warnings and Precautions 5.1)]. Advise patients that they should report any of the following signs and symptoms of liver problems to their healthcare provider right away [see Warnings and Precautions (5.2)]. yellowing of the skin or the whites of the eyes (jaundice) unusual darkening of the urine unusual tiredness right upper stomach area pain confusion swelling of the stomach area (abdomen) Advise patients that thrombocytopenia and risk of bleeding may reoccur upon discontinuing eltrombopag for oral suspension, particularly if eltrombopag for oral suspension is discontinued while the patient is on anticoagulants or antiplatelet agents. Advise patients that during therapy with eltrombopag for oral suspension, they should continue to avoid situations or medications that may increase the risk for bleeding. Advise patients that too much eltrombopag for oral suspension may result in excessive platelet counts and risk for thrombotic/thromboembolic complications [see Warnings and Precautions (5.4)]. Advise patients to have baseline ocular examination prior to administration of eltrombopag for oral suspension and be monitored for signs and symptoms of cataracts during therapy [see Warnings and Precautions (5.5)]. Advise patients to take eltrombopag for oral suspension at least hours before or hours after calcium-rich foods, mineral supplements, and antacids which contain polyvalent cations, such as iron, calcium, aluminum, magnesium, selenium, and zinc [see Dosage and Administration (2.4), Drug Interactions (7.1)]. Advise women not to breastfeed during treatment with eltrombopag for oral suspension [see Use in Specific Populations (8.2)]. For patients with persistent or chronic ITP, therapy with eltrombopag for oral suspension is administered to achieve and maintain platelet count greater than or equal to 50 10 9/L as necessary to reduce the risk for bleeding [see Indications and Usage (1.1)]. For patients with chronic hepatitis C, therapy with eltrombopag for oral suspension is administered to achieve and maintain platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin [see Indications and Usage 1.2)]. Advise patients to take eltrombopag for oral suspension without meal or with meal low in calcium (<= 50 mg) and at least hours before or hours after other medications (e.g., antacids) and calcium-rich foods [see Dosage and Administration 2.4)]. Prior to use of the oral suspension, ensure patients or caregivers receive training on proper dosing, preparation, and administration [see Dosage and Administration (2.4)]. Inform patients or caregivers how many packets to administer to get the full dose [see Instructions for Use]. Inform patients or caregivers to use new oral dosing syringe to prepare each dose of eltrombopag for oral suspension see Instructions for Use]. eltrombopagfororalsuspensioncamberlogo.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Lactation: Advise women not to breastfeed during treatment. 8.2) Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information. 8.1 Pregnancy. Risk Summary Available data from small number of published case reports and postmarketing experience with eltrombopag use in pregnant women are insufficient to assess any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction and developmental toxicity studies, oral administration of eltrombopag to pregnant rats during organogenesis resulted in embryolethality and reduced fetal weights at maternally toxic doses. These effects were observed at doses resulting in exposures that were six times the human clinical exposure based on area under the curve (AUC) in patients with persistent or chronic ITP at 75 mg/day, and three times the AUC in patients with chronic hepatitis at 100 mg/day (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an early embryonic development study, female rats received oral eltrombopag at doses of 10, 20, or 60 mg/kg/day (0.8, 2, and times, respectively, the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 0.3, 1, and times, respectively, the human clinical exposure based on AUC in patients with chronic hepatitis at 100 mg/day). Increased pre-and post-implantation loss and reduced fetal weight were observed at the highest dose which also caused maternal toxicity. In an embryo-fetal development study eltrombopag was administered orally to pregnant rats during the period of organogenesis at doses of 10, 20, or 60 mg/kg/day (0.8, 2, and times, respectively, the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 0.3, 1, and times, respectively, the human clinical exposure based on AUC in patients with chronic hepatitis at 100 mg/day). Decreased fetal weights (6% to 7%) and slight increase in the presence of cervical ribs were observed at the highest dose which also caused maternal toxicity. However, no evidence of major structural malformations was observed. In an embryo-fetal development study eltrombopag was administered orally to pregnant rabbits during the period of organogenesis at doses of 30, 80, or 150 mg/kg/day (0.04, 0.3, and 0.5 times, respectively, the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 0.02, 0.1, and 0.3 times, respectively, the human clinical exposure based on AUC in patients with chronic hepatitis at 100 mg/day). No evidence of fetotoxicity, embryolethality, or teratogenicity was observed. In pre-and post-natal developmental toxicity study in pregnant rats (F0), oral eltrombopag was administered from gestation Day through lactation Day 20. No adverse effects on maternal reproductive function or on the development of the offspring (F1) were observed at doses up to 20 mg/kg/day (2 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and similar to the human clinical exposure based on AUC in patients with chronic hepatitis at 100 mg/day). Eltrombopag was detected in the plasma of offspring (F1). The plasma concentrations in pups increased with dose following administration of drug to the F0 dams. 8.2 Lactation. Risk Summary There are no data regarding the presence of eltrombopag or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. However, eltrombopag was detected in the pups of lactating rats 10 days postpartum suggesting the potential for transfer during lactation. Due to the potential for serious adverse reactions in breastfed child from eltrombopag, breastfeeding is not recommended during treatment. 8.3 Females and Males of Reproductive Potential. Contraception Based on animal reproduction studies, eltrombopag can cause fetal harm when administered to pregnant woman. Sexually-active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) when using eltrombopag during treatment and for at least days after stopping treatment with eltrombopag. 8.4 Pediatric Use. The safety and efficacy of eltrombopag have been established in pediatric patients year and older with persistent or chronic ITP. Safety and efficacy in pediatric patients below the age of year with ITP have not been established. Safety and efficacy in pediatric patients with thrombocytopenia associated with chronic hepatitis and refractory severe aplastic anemia have not been established. The safety and efficacy of eltrombopag in pediatric patients year and older with persistent or chronic ITP were evaluated in two double-blind, placebo-controlled trials [see Adverse Reactions (6.1), Clinical Studies (14.1)]. The pharmacokinetics of eltrombopag have been evaluated in 168 pediatric patients year and older with ITP dosed once daily [see Clinical Pharmacology (12.3)]. See Dosage and Administration 2.1) for dosing recommendations for pediatric patients year and older. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information. 8.5 Geriatric Use. Of the 106 patients in two randomized clinical trials of eltrombopag 50 mg in persistent or chronic ITP, 22% were 65 years of age and over, while 9% were 75 years of age and over. Of the 1439 patients in two randomized clinical trials of eltrombopag in patients with chronic hepatitis and thrombocytopenia, 7% were 65 years of age and over, while 1% were 75 years of age and over. Of the 196 patients who received eltrombopag for the treatment of severe aplastic anemia, 18% were 65 years of age and over, while 3% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these patients and younger patients.. 8.6 Hepatic Impairment. Patients with Persistent or Chronic ITP and Severe Aplastic Anemia Reduce the initial dose of eltrombopag in patients with persistent or chronic ITP (adult and pediatric patients years and older only) or refractory severe aplastic anemia who also have hepatic impairment (Child-Pugh class A, B, C) [see Dosage and Administration (2.1, 2.3), Warnings and Precautions (5.2), Clinical Pharmacology (12.3)]. Patients with Chronic Hepatitis No dosage adjustment is recommended in patients with chronic hepatitis and hepatic impairment [see Clinical Pharmacology 12.3)]. 8.7 Ethnicity. Reduce the initial dose of eltrombopag for patients of East-/Southeast-Asian ancestry with ITP (adult and pediatric patients years and older only) or severe aplastic anemia [see Dosage and Administration 2.1, 2.3), Clinical Pharmacology 12.3)]. No reduction in the initial dose of eltrombopag is recommended in patients of East-/Southeast-Asian ethnicity with chronic hepatitis [See Clinical Pharmacology 12.3)]. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Hepatotoxicity:Monitor liver function before and during therapy. 5.2) Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia.( 5.3) Thrombotic/Thromboembolic Complications:Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag. Monitor platelet counts regularly. 5.4) Hepatotoxicity:Monitor liver function before and during therapy. 5.2) Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia.( 5.3) Thrombotic/Thromboembolic Complications:Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag. Monitor platelet counts regularly. 5.4) 5.1 Hepatic Decompensation in Patients With Chronic Hepatitis C. In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. In two controlled clinical trials in patients with chronic hepatitis and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with eltrombopag plus antivirals (7%) than the placebo plus antivirals arm (4%). Patients with low albumin levels (less than 3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score greater than or equal to 10 at baseline had greater risk for hepatic decompensation on the arm receiving treatment with eltrombopag plus antivirals. Discontinue eltrombopag if antiviral therapy is discontinued.. 5.2 Hepatotoxicity. Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity [see Adverse Reactions 6.1)] One patient (< 1%) with ITP treated with eltrombopag in clinical trials experienced drug-induced liver injury. Eleven patients (1%) with chronic hepatitis treated with eltrombopag in clinical trials experienced drug-induced liver injury. Treatment of ITP, Chronic Hepatitis C-associated Thrombocytopenia, and Refractory Severe Aplastic Anemia Measure serum ALT, AST, and bilirubin prior to initiation of eltrombopag, every weeks during the dose adjustment phase, and monthly following establishment of stable dose. Eltrombopag inhibits UDP-glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which may lead to indirect hyperbilirubinemia. If bilirubin is elevated, perform fractionation. Evaluate abnormal serum liver tests with repeat testing within to days. If the abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized. Discontinue eltrombopag if ALT levels increase to greater than or equal to x ULN in patients with normal liver function or greater than or equal to x baseline (or greater than x ULN, whichever is the lower) in patients with pre-treatment elevations in transaminases and are: progressively increasing, or persistent for greater than or equal to weeks, or accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation. If the potential benefit for reinitiating treatment with eltrombopag is considered to outweigh the risk for hepatotoxicity, then consider cautiously reintroducing eltrombopag and measure serum liver tests weekly during the dose adjustment phase. Hepatotoxicity may reoccur if eltrombopag is reinitiated. If liver test abnormalities persist, worsen, or recur, then permanently discontinue eltrombopag.. progressively increasing, or persistent for greater than or equal to weeks, or accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation. 5.3 Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia. randomized, double-blind, placebo-controlled, multicenter trial in patients with International Prognostic Scoring System (IPSS) intermediate-1, intermediate-2 or high risk MDS with thrombocytopenia, receiving azacitidine in combination with either eltrombopag (n 179) or placebo (n 177) was terminated due to lack of efficacy and safety reasons, including increased progression to acute myeloid leukemia (AML). Patients received eltrombopag or placebo at starting dose of 200 mg once daily, up to maximum of 300 mg once daily, in combination with azacitidine for at least six cycles. The incidence of death (overall survival) was 32% (57/179) in the eltrombopag arm versus 29% (51/177) in the placebo arm (HR [95% CI] 1.42 [0.97, 2.08], showing an increased relative risk of death in this trial by 42% in the eltrombopag arm). The incidence of progression to AML was 12% (21/179) in the eltrombopag arm versus 6% (10/177) in the placebo arm (HR [95% CI] 2.66 [1.31, 5.41], showing an increased relative risk of progression to AML in this trial by 166% in the eltrombopag arm).. 5.4 Thrombotic/Thromboembolic Complications. Thrombotic/thromboembolic complications may result from increases in platelet counts with eltrombopag. Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.Consider the potential for an increased risk of thromboembolism when administering eltrombopag to patients with known risk factors for thromboembolism (e.g., Factor Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). To minimize the risk for thrombotic/thromboembolic complications, do not use eltrombopag in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain target platelet counts [see Dosage and Administration 2.1, 2.2, 2.3)]. In two controlled clinical trials in patients with chronic hepatitis and thrombocytopenia, 3% (31/955) treated with eltrombopag experienced thrombotic event compared with 1% (5/484) on placebo. The majority of events were of the portal venous system (1% in patients treated with eltrombopag versus less than 1% for placebo). In controlled trial in patients with chronic liver disease and thrombocytopenia not related to ITP undergoing elective invasive procedures (N 292), the risk of thrombotic events was increased in patients treated with 75 mg of eltrombopag once daily. Seven thrombotic complications (six patients) were reported in the group that received eltrombopag and three thrombotic complications were reported in the placebo group (two patients). All of the thrombotic complications reported in the group that received eltrombopag were portal vein thrombosis (PVT). Symptoms of PVT included abdominal pain, nausea, vomiting, and diarrhea. Five of the six patients in the group that received eltrombopag experienced thrombotic complication within 30 days of completing treatment with eltrombopag and at platelet count above 200 10 9/L. The risk of portal venous thrombosis was increased in thrombocytopenic patients with chronic liver disease treated with 75 mg of eltrombopag once daily for weeks in preparation for invasive procedures. 5.5 Cataracts. In the three controlled clinical trials in adults with persistent or chronic ITP, cataracts developed or worsened in 15 (7%) patients who received 50 mg of eltrombopag daily and (7%) placebo-group patients. In the extension trial, cataracts developed or worsened in 11% of patients who underwent ocular examination prior to therapy with eltrombopag. In the two controlled clinical trials in patients with chronic hepatitis and thrombocytopenia, cataracts developed or worsened in 8% of patients treated with eltrombopag and 5% of patients treated with placebo. Cataracts were observed in toxicology studies of eltrombopag in rodents [see Nonclinical Toxicology (13.2)]. Perform baseline ocular examination prior to administration of eltrombopag and, during therapy with eltrombopag, regularly monitor patients for signs and symptoms of cataracts. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporations PROMACTA (R)(eltrombopag) for oral suspension. However, due to Novartis Pharmaceuticals Corporations marketing exclusivity rights, this drug product is not labeled with that information.